• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. Aluminium coordination complexes in copolymerization reactions of carbon dioxide and epoxides
  Nduka Ikpo,Jenna C. Flogeras,Francesca M. Kerton Dalton Trans., 2013,42, 8998-9006
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid (CAS No. 1006319-26-1)

4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid, identified by its CAS number 1006319-26-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and agrochemical research. This compound belongs to the pyrazole derivatives, a class of heterocyclic compounds known for their diverse biological activities and structural versatility. The presence of both bromine and trifluoromethyl substituents in its molecular structure imparts unique electronic and steric properties, making it a valuable scaffold for the development of novel bioactive molecules.

The structural motif of 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid consists of a pyrazole ring functionalized with a bromo group at the 4-position and a trifluoromethyl group at the 3-position, linked to an acetic acid moiety. This specific arrangement enhances its potential as an intermediate in synthetic chemistry, particularly in the construction of more complex pharmacophores. The pyrazole core is renowned for its role in medicinal chemistry, often serving as a key component in drugs targeting various therapeutic areas, including inflammation, cancer, and infectious diseases.

In recent years, the demand for fluorinated compounds in drug discovery has surged due to their ability to improve metabolic stability, binding affinity, and pharmacokinetic properties. The trifluoromethyl group, in particular, is a widely employed pharmacophore that enhances the bioavailability and efficacy of many therapeutic agents. Its electron-withdrawing nature increases the lipophilicity of molecules while maintaining metabolic resistance, making it an attractive feature in drug design. The incorporation of this group into 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid underscores its potential utility in generating novel compounds with enhanced pharmacological profiles.

The bromo substituent at the 4-position of the pyrazole ring further contributes to the compound's reactivity and diversity. Bromine is a versatile halogen that can participate in various chemical transformations, including cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings. These reactions are fundamental tools in organic synthesis, enabling the introduction of aryl or amino groups into complex molecular frameworks. Consequently, 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid serves as an excellent starting material for constructing more elaborate structures with tailored biological activities.

Recent advancements in medicinal chemistry have highlighted the importance of pyrazole derivatives in addressing unmet medical needs. Studies have demonstrated that modifications within the pyrazole scaffold can significantly alter biological activity, leading to the identification of potent inhibitors and agonists. For instance, derivatives featuring fluorinated or halogenated substituents have shown promise in preclinical models for cancer therapy. The structural features of 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid align well with these trends, positioning it as a candidate for further exploration in drug development.

The acetic acid moiety at the 1-position of 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid provides an additional site for functionalization, allowing chemists to diversify its applications. This carboxylic acid group can be esterified, amidated, or incorporated into peptide mimetics, expanding its utility in synthetic biology and medicinal chemistry. Such modifications are crucial for optimizing solubility, stability, and bioavailability—key factors determining a compound's success as a drug candidate.

Current research trends indicate that pyrazole derivatives continue to be a rich source of bioactive molecules. For example, recent publications have reported on pyrazole-based inhibitors targeting enzyme cascades involved in inflammation and cancer progression. The structural flexibility offered by compounds like 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid allows researchers to fine-tune interactions with biological targets through subtle adjustments to substituents or functional groups. This adaptability makes it an invaluable asset in hit-to Lead optimization programs.

The synthesis of 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid involves multi-step organic transformations that highlight modern synthetic methodologies. Key steps typically include halogenation reactions to introduce the bromo group followed by electrophilic aromatic substitution to incorporate the trifluoromethyl moiety. Advanced techniques such as palladium-catalyzed cross-coupling reactions may also be employed to construct more complex derivatives from this intermediate. These synthetic strategies reflect contemporary trends toward efficient and sustainable chemical processes.

The pharmacological potential of 4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic Acid is further underscored by its ability to serve as a precursor for diverse bioactive scaffolds. Researchers have leveraged similar pyrazole derivatives to develop compounds with anti-inflammatory, antiviral, and anticancer properties. By exploring analogs with varying substituents or linkages, scientists can uncover novel mechanisms of action and expand therapeutic applications.

In conclusion,4-Bromo-3-(trifluoromethyl)-1H-pyrazol-1-yloic acid (CAS No. 100631926) represents a compelling scaffold for pharmaceutical innovation due to its structural features and synthetic accessibility. Its combination of bromine and trifluoromethyl groups offers unique opportunities for modulating biological activity through further derivatization efforts. As research continues to uncover new applications for pyrazole-based compounds, this molecule is poised to play an important role in advancing drug discovery initiatives across multiple therapeutic domains.

• 1437794-44-9(4-Bromo-1-propyl-3-(trifluoromethyl)pyrazole)
• 926241-24-9(2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid)
• 1001500-11-3(2-4-bromo-5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-ylacetic acid)
• 1005584-44-0(2-[4-bromo-5-methyl-3-(trifluoromethyl)-1h-pyrazol-1-yl]propanoic Acid)
• 1001518-85-9(3-[4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]propanoic acid)
• 1437794-58-5(4-Bromo-1-butyl-3-(trifluoromethyl)pyrazole)
• 1006348-79-3(3-4-bromo-3-(trifluoromethyl)-1H-pyrazol-1-ylpropanoic acid)
• 1437794-62-1(4-Bromo-1-isobutyl-3-(trifluoromethyl)pyrazole)
• 299405-26-8(2-4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-ylacetic acid)
• 1005631-80-0(2-4-bromo-3-(difluoromethyl)-5-methyl-1H-pyrazol-1-ylpropanoic acid)